FDA orders clinical hold on Aprea's p53 reactivator as struggling biotech pledges to address safety concerns
Little Aprea Therapeutics just tripped yet again on its rocky path to develop a drug that can reactivate the mutant tumor suppressor protein p53. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
